Stay updated on M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.

Latest updates to the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page
- ChecktodayChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check7 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check28 days agoChange DetectedA new revision tag v3.7.0 has been added to the study history, replacing the previous v3.6.6. This indicates an update to the record in the history log.SummaryDifference0.1%

- Check50 days agoChange DetectedThe revision history shows a new entry for Revision: v3.6.6 and a removal of Revision: v3.6.5, indicating an update to the page's versioned documentation.SummaryDifference0.1%

- Check71 days agoChange DetectedThe record history shows Revision: v3.6.5 replacing v3.6.4, indicating a small maintenance update to the page’s interface. It does not change study data or outcomes.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page now shows Revision: v3.6.4 instead of Revision: v3.6.3, indicating a minor version update to the page template with no apparent changes to the study data or visible content.SummaryDifference0.1%

Stay in the know with updates to M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.